Hypothesis

Circadian misalignment of hepatic hepcidin and bone marrow ferroportin rhythms limits iron availability for erythroid progenitors during their DNA synthesis peak, driving anemia in aging. Restoring this iron‑flux rhythm by administering iron supplements at the circadian phase when ferroportin is maximal (subjective night) will normalize heme synthesis, reduce ineffective erythropoiesis, and improve hemoglobin levels in aged mice.

Mechanistic Basis

Erythroid progenitors exhibit a 24‑hour rhythm in DNA synthesis that peaks during the daytime (ZT4‑ZT8) [1]. Iron incorporation into heme must coincide with this S‑phase window; otherwise, excess labile iron fuels ROS generation and apoptosis. Hepcidin, the master iron regulator, is secreted by hepatocytes and displays a circadian oscillation that is antiphasic to ferroportin expression on marrow macrophages and endothelial cells [7]. In aged mice, loss of BMAL1 in endothelial cells flattens these rhythms, causing persistent high hepcidin and low ferroportin, which traps iron in stores and starves erythroblasts when they are primed for proliferation [5].

We propose that the aged niche retains a latent capacity for rhythmic ferroportin transcription that can be re‑entrained by an external iron cue delivered at the appropriate circadian time. By providing iron (e.g., ferrous sulfate) when ferroportin transcription is naturally rising (subjective night, ZT12‑ZT16), we increase extracellular iron export precisely when erythroid progenitors are entering their next DNA synthesis cycle, thereby coupling iron supply with demand and minimizing oxidative stress.

Predictions & Experimental Design

1. Rhythm Rescue – Aged (20‑month) C57BL/6 mice receiving iron intraperitoneally at ZT14 for 2 weeks will show restored circadian ferroportin mRNA oscillations in bone marrow macrophages (qPCR over 24 h) and flattened hepcidin rhythms will become anti‑phasic again, unlike vehicle‑treated controls.
2. Erythropoietic Output – Same treatment will increase CFU‑E colonies ex vivo by ≥2‑fold (versus aged controls) and raise peripheral hemoglobin by ≥1 g/dL, measured weekly.
3. Functional Iron Utilization – Labile iron pool (LIP) measured by Calcein‑AM quenching in sorted Ter119+ cells will be lower at ZT4‑ZT8 in treated mice, indicating reduced oxidative iron mis‑matching, while total cellular iron content remains unchanged.
4. Behavioral Control – Administering iron at the opposite phase (ZT2) will not rescue rhythms and may exacerbate anemia, confirming timing dependence.

Key readouts: (a) bone marrow ferroportin and hepcidin expression via qPCR and ELISA, (b) serum iron, transferrin saturation, and TIBC, (c) colony‑forming unit assays, (d) hemoglobin and hematocrit, (e) ROS staining (DHE) in erythroblasts.

Potential Pitfalls

• Systemic iron overload could trigger inflammation; we will limit dose to 2 mg Fe/kg and monitor liver iron stores and serum ALT.
• Age‑related changes in gut iron absorption may confound intraperitoneal results; using IP delivery bypasses this variable.
• Circadian drift in constant darkness could mask timing effects; experiments will be conducted under 12 h:12 h light‑dark cycles with zeitgeber time verified by wheel‑running activity.

If timed iron fails to restore ferroportin rhythm or improve erythropoiesis, the hypothesis that circadian iron‑flux misalignment is a primary driver of age‑related anemia would be falsified, steering focus toward alternative mechanisms such as niche‑derived inflammatory signals or intrinsic epigenetic drift in HSCs.